IMC Chicago’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $55.7M | Sell |
1,985,200
-896,500
| -31% | -$23.9M | 0.02% | 470 |
|
|
2025
Q4 | $71.8M | Buy |
2,881,700
+455,300
| +19% | +$11.5M | 0.03% | 383 |
|
|
2025
Q3 | $61.8M | Buy |
2,426,400
+289,300
| +14% | +$7.14M | 0.02% | 400 |
|
|
2025
Q2 | $51.8M | Sell |
2,137,100
-95,900
| -4% | -$2.24M | 0.02% | 368 |
|
|
2025
Q1 | $56.6M | Sell |
2,233,000
-535,600
| -19% | -$14M | 0.03% | 294 |
|
|
2024
Q4 | $73.5M | Buy |
2,768,600
+948,600
| +52% | +$25.7M | 0.03% | 258 |
|
|
2024
Q3 | $52.7M | Sell |
1,820,000
-118,100
| -6% | -$3.45M | 0.03% | 293 |
|
|
2024
Q2 | $54.2M | Buy |
1,938,100
+62,400
| +3% | +$1.72M | 0.03% | 274 |
|
|
2024
Q1 | $52.1M | Sell |
1,875,700
-459,600
| -20% | -$12.8M | 0.03% | 242 |
|
|
2023
Q4 | $67.2M | Buy |
2,335,300
+1,157,300
| +98% | +$35M | 0.05% | 204 |
|
|
2023
Q3 | $39.1M | Buy |
1,178,000
+267,300
| +29% | +$9.45M | 0.03% | 227 |
|
|
2023
Q2 | $33.4M | Buy |
910,700
+92,500
| +11% | +$3.6M | 0.03% | 266 |
|
|
2023
Q1 | $33.4M | Buy |
818,200
+96,400
| +13% | +$4.16M | 0.04% | 235 |
|
|
2022
Q4 | $37M | Sell |
721,800
-40,500
| -5% | -$1.94M | 0.06% | 202 |
|
|
2022
Q3 | $33.4M | Buy |
762,300
+30,100
| +4% | +$1.46M | 0.04% | 194 |
|
|
2022
Q2 | $38.4M | Sell |
732,200
-59,200
| -7% | -$3.02M | 0.05% | 170 |
|
|
2022
Q1 | $41M | Sell |
791,400
-624,700
| -44% | -$32.4M | 0.04% | 196 |
|
|
2021
Q4 | $83.6M | Buy |
1,416,100
+177,900
| +14% | +$8.81M | 0.07% | 126 |
|
|
2021
Q3 | $53.3M | Buy |
1,238,200
+278,200
| +29% | +$12.3M | 0.06% | 176 |
|
|
2021
Q2 | $37.6M | Sell |
960,000
-328,000
| -25% | -$12.8M | 0.05% | 215 |
|
|
2021
Q1 | $46.7M | Buy |
+1,288,000
| New | +$45.7M | 0.07% | 157 |
|
|
2020
Q4 | – | Sell |
-672,979
| Closed | -$23.4M | – | 1089 |
|
|
2020
Q3 | $23.4M | Buy |
672,979
+358,044
| +114% | +$12.6M | 0.04% | 174 |
|
|
2020
Q2 | $9.77M | Sell |
314,935
-26,456
| -8% | -$899K | 0.02% | 267 |
|
|
2020
Q1 | $10.6M | Buy |
341,391
+74,202
| +28% | +$2.53M | 0.02% | 211 |
|
|
2019
Q4 | $9.93M | Sell |
267,189
-20,975
| -7% | -$747K | 0.03% | 214 |
|
|
2019
Q3 | $9.82M | Buy |
288,164
+31,304
| +12% | +$1.14M | 0.03% | 183 |
|
|
2019
Q2 | $10.6M | Buy |
256,860
+47,641
| +23% | +$1.89M | 0.03% | 166 |
|
|
2019
Q1 | $8.43M | Sell |
209,219
-738
| -0.4% | -$29.6K | 0.03% | 164 |
|
|
2018
Q4 | $8.7M | Buy |
+209,957
| New | +$8.72M | 0.03% | 137 |
|
Other funds holding PFE
VCM
VPM
IMC Chicago's PFE Position: Q3 2025 in Review
IMC Chicago sold out of Pfizer (PFE) in Q3 2025, closing a stake of 106,092 shares — an estimated $2.62M sold.
IMC Chicago first reported a position in PFE in Q3 2019 and held it in 7 quarters. The position peaked at $3.63M in Q1 2022. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.
- IMC Chicago reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
- IMC Chicago sold 106,092 Pfizer shares in Q3 2025, an estimated $2.62M.
- IMC Chicago first reported a position in Pfizer in Q3 2019 and held it in 7 quarters.
- IMC Chicago's Pfizer position peaked at $3.63M in Q1 2022.
- 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.
Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.